Finance

Beta
Lists
COR:NYSE
Cencora Inc
$269.36
+0.62%
(+1.65) 1D
$269.36
0.00% (0.00)
After hours
Closed: May 29, 4:00:12 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COR...
Open
$270.42
High
$272.27
Low
$266.25
Mkt. cap
11.91B
Avg. vol.
2.06M
Volume
3.11M
52-wk high
$377.54
52-wk low
$244.82
Beta
0.64
Shares outstanding
194.56M
No. of employees
49K
Open
$270.42
High
$272.27
Low
$266.25
Mkt. cap
11.91B
Avg. vol.
2.06M
Volume
3.11M
52-wk high
$377.54
52-wk low
$244.82
Beta
0.64
Shares outstanding
194.56M
No. of employees
49K
News stories
From sources across the web
Profile
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment. Wikipedia
About Cencora Inc
CEORobert P. Mauch Ph.D.
Employees49K
Founded1871
Headquarters-
SectorHealth care provider
Websitecencora.com
Last report
May 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$4.75 / $4.73
+0.48%beat
Revenue / Est. (USD)
78.36B / 81.04B
-3.31%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
80.66B
83.73B
85.93B
78.36B
Cost of goods sold
77.77B
80.78B
82.87B
74.78B
Cost of revenue
77.77B
80.78B
82.87B
74.78B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.67B
1.75B
1.80B
1.98B
Operating expense
1.93B
2.00B
2.06B
2.23B
Total operating expenses
79.69B
82.78B
84.93B
77.01B
Operating income
969.58M
944.58M
1.00B
1.34B
Other non operating income
17.42M
-49.91M
10.10M
-173.00K
EBT including unusual items
896.28M
-187.04M
708.64M
2.09B
EBT excluding unusual items
931.21M
795.23M
941.56M
1.20B
Income tax expense
206.53M
146.03M
142.51M
459.04M
Effective tax rate
23.04%
-78.07%
20.11%
21.98%
Other operating expenses
1.16M
-4.00M
362.00K
595.00K
Net income
687.40M
-339.70M
559.65M
1.64B
Net profit margin
0.85%
-0.41%
0.65%
2.09%
Earnings per share
4.00
3.84
4.08
4.75
Interest and investment income
35.10M
31.52M
20.95M
13.88M
Interest expense
-116.90M
-109.36M
-93.36M
-154.34M
Net interest expenses
-81.79M
-77.83M
-72.41M
-140.46M
Depreciation and amortization charges
128.13M
131.49M
134.29M
132.14M
EBITDA
1.23B
1.21B
1.27B
1.60B
Gain or loss from assets sale
-
-
-35.82M
-234.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer